PTAB challenges

Proceedings overview

One AIA trial proceeding, IPR2026-00168, has been filed against US patent 12123880. This proceeding is currently in "Institution Denied" status, meaning the Patent Trial and Appeal Board (PTAB) declined to initiate a full review of the challenged claims. This outcome strengthens the patent's defensive posture as no claims have been challenged or invalidated through this IPR.

IPR2026-00168 — Sarepta Therapeutics, Inc. et al. v. Genzyme Corp

• Type: Inter Partes Review
• Filed: 2025-12-02
• Status: Institution Denied. The PTAB declined to institute a trial on the challenged claims.
• Judge panel: Not publicly available from the search results at this stage.
• Petition grounds: The petition challenged claims 1-20 of US Patent 12,123,880. The grounds for the challenge were based on obviousness under 35 U.S.C. § 103, citing various prior art references including US 2020/0392556 (Shukla), WO 2017/031590 (Sarepta), and a combination of documents including US 2020/0030467 (Bennett) and US 2017/0121703 (Bennett). The petitioner argued that the claims were obvious over these references, particularly regarding methods for detecting AAV and determining heterogeneity using LC/MS.
• Institution decision: Denied on 2026-05-15. The PTAB panel denied institution, finding that the petition did not demonstrate a reasonable likelihood that the petitioner would prevail with respect to at least one of the challenged claims. The Board determined that the petitioner failed to adequately demonstrate obviousness, specifically in combining the various references to arrive at the claimed invention, particularly regarding the use of LC/MS for AAV serotyping and heterogeneity determination.
• Final Written Decision (if issued): Not applicable, as institution was denied.
• Settlement / termination: Not applicable.
• Appeal: No appeal to the Federal Circuit has been filed, given that institution was denied.
• Defensive value: The denial of institution means that all claims (1-20) of US12123880 remain intact and have not been challenged or cancelled by the PTAB. This indicates that the initial obviousness arguments presented by Sarepta Therapeutics, Inc. et al. were not persuasive enough to warrant a full review by the Board, which can be a strong signal for a patent owner in asserting the patent.

Strategic summary

All twenty claims (claims 1-20) of US patent 12123880 remain UNTESTED by the PTAB, as the sole IPR petition filed (IPR2026-00168) was denied institution. This means that the patent has not been narrowed, nor have any claims been invalidated or sustained by a PTAB Final Written Decision. The patent owner, Genzyme Corp, successfully defended against the initial challenge to the patentability of its claims.

From an estoppel perspective, 35 U.S.C. § 315(e)(2) applies only to claims that proceed to a final written decision. Since institution was denied for IPR2026-00168, no statutory estoppel applies to the petitioner (Sarepta Therapeutics, Inc. et al.) or their privies for the grounds raised in that petition. This means that, theoretically, the same or related prior art arguments could potentially be raised again in future challenges, although the PTAB's reasoning for denying institution would likely need to be addressed and overcome with new arguments or evidence. For a defendant currently being asserted against, all prior-art grounds remain available for potential future challenges, provided they can articulate arguments that would satisfy the PTAB's institution threshold.

There are no apparent pattern signals of multiple IPRs by the same petitioner or aggressive PTAB appeals by the patent owner at this time, as only one IPR has been filed, and it did not proceed to trial. Unified Patents is listed as a petitioner in the Google Patents listing for the IPR, but the official filing data specifies "Sarepta Therapeutics, Inc. et al.", suggesting Unified Patents may be associated with monitoring or coordinating the petition rather than being the direct petitioner itself.

Recommended next steps

As a defendant facing assertion of this patent, it is crucial to review the PTAB's "Institution Denied" decision for IPR2026-00168. Understanding the specific reasoning behind the denial can inform whether alternative invalidity arguments, perhaps drawing on different prior art or presenting the existing art in a novel way, might still be viable. The decision can be found on the USPTO PTAB Decisions portal: IPR2026-00168.

Given the current status, all claims of US12123880 are considered valid as far as PTAB proceedings are concerned. If you are considering filing your own IPR, a thorough analysis of the denied petition's arguments and the Board's reasoning is essential to avoid repeating the same deficiencies.
There are no active proceedings pending, and all claims are currently untested in an AIA trial. The absence of further PTAB challenges after an institution denial might indicate that potential petitioners find it difficult to meet the institution threshold, or that the patent owner's arguments during the preliminary response were particularly strong. However, this also means that the patent has not undergone the rigorous scrutiny of a full IPR trial, leaving open the possibility for new challenges.## Proceedings overview
One AIA trial proceeding, IPR2026-00168, has been filed against US patent 12123880 and is currently in "Institution Denied" status. This means the PTAB declined to initiate a full review of the challenged claims, resulting in all claims remaining intact and untested by the Board. This outcome strengthens the patent's defensive posture as no claims have been invalidated.

IPR2026-00168 — Sarepta Therapeutics, Inc. et al. v. Genzyme Corp

• Type: Inter Partes Review
• Filed: 2025-12-02
• Status: Institution Denied. The PTAB declined to institute a trial on the challenged claims.
• Judge panel: Not publicly available from the search results at this stage.
• Petition grounds: The petition challenged claims 1-20 of US Patent 12,123,880. The grounds for the challenge were based on obviousness under 35 U.S.C. § 103, citing various prior art references including US 2020/0392556 (Shukla), WO 2017/031590 (Sarepta), and a combination of documents including US 2020/0030467 (Bennett) and US 2017/0121703 (Bennett). The petitioner argued that the claims were obvious over these references, particularly regarding methods for detecting AAV and determining heterogeneity using LC/MS.
• Institution decision: Denied on 2026-05-15. The PTAB panel denied institution, finding that the petition did not demonstrate a reasonable likelihood that the petitioner would prevail with respect to at least one of the challenged claims. The Board determined that the petitioner failed to adequately demonstrate obviousness, specifically in combining the various references to arrive at the claimed invention, particularly regarding the use of LC/MS for AAV serotyping and heterogeneity determination.
• Final Written Decision (if issued): Not applicable, as institution was denied.
• Settlement / termination: Not applicable.
• Appeal: No appeal to the Federal Circuit has been filed, given that institution was denied.
• Defensive value: The denial of institution means that all claims (1-20) of US12123880 remain intact and have not been cancelled by the PTAB. This outcome suggests that the initial obviousness arguments presented by Sarepta Therapeutics, Inc. et al. were not persuasive enough to warrant a full review by the Board, which can be a strong signal for a patent owner in asserting the patent.

Strategic summary

All twenty claims (claims 1-20) of US patent 12123880 remain UNTESTED by the PTAB, as the sole IPR petition filed (IPR2026-00168) was denied institution. This means that the patent has not been narrowed, nor have any claims been invalidated or sustained by a PTAB Final Written Decision. The patent owner, Genzyme Corp, successfully defended against the initial challenge to the patentability of its claims.

From an estoppel perspective, 35 U.S.C. § 315(e)(2) applies only to claims that proceed to a final written decision. Since institution was denied for IPR2026-00168, no statutory estoppel applies to the petitioner (Sarepta Therapeutics, Inc. et al.) or their privies for the grounds raised in that petition. This means that, theoretically, the same or related prior art arguments could potentially be raised again in future challenges, although the PTAB's reasoning for denying institution would likely need to be addressed and overcome with new arguments or evidence. For a defendant currently being asserted against, all prior-art grounds remain available for potential future challenges, provided they can articulate arguments that would satisfy the PTAB's institution threshold.

There are no apparent pattern signals of multiple IPRs by the same petitioner or aggressive PTAB appeals by the patent owner at this time, as only one IPR has been filed, and it did not proceed to trial. Unified Patents is listed in the Google Patents summary as having filed the IPR, but the official "PTAB proceedings on file" list from the USPTO Open Data Portal specifies Sarepta Therapeutics, Inc. et al. as the petitioner.

Recommended next steps

As a defendant facing assertion of this patent, it is crucial to review the PTAB's "Institution Denied" decision for IPR2026-00168. Understanding the specific reasoning behind the denial can inform whether alternative invalidity arguments, perhaps drawing on different prior art or presenting the existing art in a novel way, might still be viable. The decision can be found on the USPTO PTAB Decisions portal: IPR2026-00168.

Given the current status, all claims of US12123880 are considered valid as far as PTAB proceedings are concerned. If you are considering filing your own IPR, a thorough analysis of the denied petition's arguments and the Board's reasoning is essential to avoid repeating the same deficiencies. There are no active proceedings pending, and all claims are currently untested in an AIA trial. The absence of further PTAB challenges after an institution denial might indicate that potential petitioners find it difficult to meet the institution threshold, or that the patent owner's arguments during the preliminary response were particularly strong. However, this also means that the patent has not undergone the rigorous scrutiny of a full IPR trial, leaving open the possibility for new challenges.